Lv7
5590 积分 2023-02-21 加入
盐酸环丙沙星合成与结晶过程的研究
4个月前
已完结
麝香系统溶液结晶溶剂选择的研究
4个月前
已完结
FIGO-Ⅰ期卵巢透明细胞癌患者预后分析
9个月前
已完结
Ⅰ期卵巢透明细胞癌患者临床病理特点及预后分析——北京协和医院12年临床资料回顾性分析
9个月前
已完结
基于GC-MS探讨肝脏再生代谢变化规律及相关代谢标志物的研究
10个月前
已完结
Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors
1年前
已完结
Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors
1年前
已完结
The synthesis and evaluation of sulfonamide derivatives target EGFR790M/L858R mutations and ALK rearrangement as anticancer agents
1年前
已完结
Identification of highly potent 2,4‐diarylaminopyrimidine analogs of a typical piperidinyl‐4‐ol moiety as promising antitumor ALK inhibitors
1年前
已完结
Preclinical characterization of PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader
2天前
已采纳
Abstract B024: RAS(ON) G12D- and Multi-selective inhibitor doublet drives complete responses in combination with anti-PD-1 in a preclinical model of MSS KRAS G12D mutant CRC
3天前
已采纳
Abstract 1838: LBL-024, an anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model
8天前
已采纳
Abstract 1068: SDX-7320, a novel inhibitor of methionine aminopeptidase 2 (MetAP2), inhibits MCF-7 tumor growth in combination with palbociclib (Ibrance®)
9天前
已采纳
Advances and challenges in RAS signaling targeted therapy in leukemia
10天前
已采纳
Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death
1个月前
已采纳
Data from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
1个月前
已采纳
Abstract B123: Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
1个月前
已采纳
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies
1个月前
已采纳
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies
1个月前
已驳回
皖公网安备34019202002308
